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Objectives The authors sought to describe the association between post-procedural bleeding and
long-term recurrent bleeding, major adverse cardiac events (MACE), and mortality among older pa-
tients undergoing percutaneous coronary intervention (PCI).
Background Bleeding complications after PCI are associated with an increased risk for acute mor-
bidity and long-term mortality, but the association of these bleeding complications with other
events is unknown.
Methods Patients entered into the National Cardiovascular Data Registry (NCDR) CathPCI Registry
(n  461,311; 946 sites) from January 2004 to December 2008 were linked with claims from the
Centers for Medicare & Medicaid Services and grouped according to in-hospital post-PCI bleeding.
The association between post-PCI bleeding and 1-, 12-, and 30-month readmission for bleeding,
MACE, and all-cause mortality was examined with Cox regression that included patient and proce-
dural characteristics using no bleeding as the reference.
Results Overall, 3.1% (n  14,107) of patients experienced post-PCI bleeding. Patients who bled
were older, more often female, had more medical comorbidities, less often received bivalirudin, and
more often underwent PCI via the femoral approach. After adjustment, bleeding after the index pro-
cedure was signiﬁcantly associated with readmission for bleeding (adjusted hazard ratios [95% conﬁ-
dence interval]: 1 month, 1.54 [1.42 to 1.67]; 12 months, 1.52 [1.40 to 1.66]; 30 months, 1.29 [1.11 to
1.50]), MACE (1 month, 1.11 [1.07 to 1.15]; 12 months, 1.17 [1.13 to 1.21]; 30 months, 1.12 [1.06 to
1.19]) and all-cause mortality (1 month, 1.32 [1.26 to 1.38]; 12 months, 1.33 [1.27 to 1.40]);
30 months, 1.22 [1.15 to 1.30]).
Conclusions Post-PCI bleeding complications are associated with an increased risk for short- and
long-term recurrent bleeding, MACE, and all-cause mortality. These data underscore the prognostic
importance of periprocedural bleeding and the need for identifying strategies to reduce long-term
bleeding risk among patients undergoing PCI. (J Am Coll Cardiol Intv 2012;5:958–65) © 2012 by
the American College of Cardiology Foundation
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959Bleeding complications that occur after percutaneous coro-
nary intervention (PCI) are associated with an increased risk
for morbidity and all-cause mortality (1). Mechanisms
underlying this association are unclear but likely include
cessation of evidence-based medical therapy (2); blood
transfusion (1); the effect of comorbidities among patients
who develop bleeding (3); or the effect of bleeding itself
when bleeding is intracranial or retroperitoneal. Despite the
lack of clarity on the pathophysiological explanations, the
adverse prognostic impact of bleeding has been noted in
the outpatient setting as well, with up to 11% of patients
discontinuing at least 1 antiplatelet agent due to so-called
“nuisance” bleeding (4). Identification of patients at high
bleeding risk has been proposed as a way to selectively
implement “bleeding avoidance strategies” (5,6).
Most studies examining the prognostic impact of bleed-
ing have examined outcomes associated with either in-
hospital (5) or out-of-hospital bleeding (7), but not both. In
addition, these studies have primarily examined mortality or
ischemic events as the outcome; few studies have assessed
the relationship between acute bleeding and both recurrent
bleeding and ischemic events that occur over the long term.
It remains unclear whether patients who develop hemor-
rhagic complications after PCI continue to be at risk for
bleeding complications long after the procedure. This is an
important issue, given the need for prolonged antithrom-
botic therapy for secondary prevention (8,9) and the differ-
ential bleeding profiles of various evidence-based discharge
antithrombotic therapies. Accordingly, we used a large
contemporary registry of patients undergoing PCI to
examine the association between post-PCI bleeding and
long-term outcomes, including readmission for bleeding
events.
Methods
Patient population. The National Cardiovascular Data
egistry (NCDR) CathPCI Registry, which is cosponsored
y the American College of Cardiology and the Society for
ardiovascular Angiography and Interventions, has been
reviously described (10). The CathPCI Registry collects
ata on patient and hospital characteristics, clinical presen-
ation, treatments, and outcomes for PCI procedures from
ver 1,000 sites across the United States. Data are entered
nto NCDR-certified software at participating institutions,
nd exported in a standard format to the American College
f Cardiology. There is a comprehensive data quality
rogram, including both data quality report specifications
or data capture and transmission, and an auditing program.
committee of the American College of Cardiology
rospectively defined the variables, which are available at the
CDR website.
For the purpose of this analysis, we included the first PCIrocedure performed in any individual patient during aualifying hospitalization between January 2004 and De-
ember 2008. The dataset comprised 1,725,600 admissions
rom 967 sites. Patients who died during hospitalization (n 
2,029) and patients for whom bleeding data were missing
n  61; 1 site) were excluded. The study was approved by
he institutional review board of Duke University Medical
enter, which determined that the study met the definition
f research not requiring informed consent.
Linkage to claims data. The CathPCI Registry only con-
ains data on in-hospital outcomes. In order to determine
he association between in-hospital bleeding complications
nd longer-term outcomes, we linked CathPCI Registry
atients over the age of 65 years with the Medicare 100%
art A claims file (11). Percutaneous coronary intervention
rocedure codes (International Classification of Diseases-
inth Revision-Clinical Modification [ICD-9-CM],
0.66, 36.0x, 37.22, 37.23, and 88.5x, except 88.59) were
sed to identify index procedures in the Medicare files,
hich were then linked to the CathPCI Registry using
ndirect identifiers (non-unique fields that when used in
ombination may identify unique hospitalizations). Linking
ules used a hierarchy of evi-
ence approach such that rules
ith the greatest specificity were
pplied first. Once a match was
chieved for a patient, no further
ules were applied. The linking
ules contained combinations of
nformation denoting the index
CI procedure site, patient date
f birth or age, admission, discharge
ate, and sex. If a single CathPCI
egistry record matched with mul-
iple Medicare records using the same rules, then no linking
ccurred. Unidentified longitudinal profiles were obtained
ith up to 30 months of patient follow-up. Sites that did
ot match to Medicare records and patients whose index
CI procedure did not occur during a period of fee-for-
ervice enrollment were excluded. This study included all
edicare-linked patients 65 years of age undergoing PCI
ho were enrolled in the CathPCI Registry from January 1,
004, to December 31, 2008.
Endpoints and deﬁnitions. The outcomes for this analysis
were readmission for bleeding, major adverse cardiac events
(MACE) (defined as the composite of death, myocardial
infarction [MI], or revascularization), and all-cause mortal-
ity. Outcomes were evaluated at 1 month, 12 months, and
30 months. We also examined the use of evidence-based
medications at hospital discharge (defined as the prescrip-
tion of aspirin, clopidogrel, beta-blockers, statins, and
angiotensin-converting enzyme inhibitors) between patients
who bled versus those who did not, and compared length of
Abbreviations
and Acronyms
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionstay between the 2 groups.
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960To identify patients who experienced post-PCI bleeding,
we used the definition of bleeding in the CathPCI Registry
(i.e., access site bleeding, retroperitoneal bleeding, gastro-
intestinal bleeding, genitourinary bleeding, or other). All
bleeding events in the registry are further defined as requir-
ing transfusion and/or prolonging the hospital stay, and/or
causing a drop in hemoglobin 3.0 g/dl. Hematomas 10
cm for femoral access or 2 cm for radial access qualify as
access site bleeding. We also grouped patients according to
access site bleeding, defined as overt access site bleeding or
retroperitoneal bleeding, and non-access site bleeding, de-
fined as all other bleeding events. Readmissions for bleed-
ing were identified from claims data using the ICD-
9-CM diagnosis codes: Bleeding 430 to 432, 578.X,
719.1X, 423.0, 599.7, 626.2, 626.6, 626.8, 627.0, 627.1,
786.3, 784.7, or 459.0. Myocardial infarction and revas-
cularization events that occurred during follow-up were
obtained from claims data using the ICD-9-CM diag-
nosis code 410.X1 (MI) and ICD-9-CM procedure codes
36.00, 36.06, 36.07, 36.09, and 36.10 to 36.19 (revascu-
larization). Only revascularizations occurring after dis-
charge from the index hospital stay were included for the
MACE endpoint. All-cause mortality was obtained from
the claims data file.
Statistical analysis. Patients were grouped according to
hether they experienced a post-procedure bleeding event.
or descriptive analyses, baseline characteristics and treat-
ent strategies were compared between patients who bled
ersus those who did not. Continuous variables are pre-
Figure 1. Study Sample Selection Flow Diagram
Displays initial study population through the ﬁnal study population, exclusions
Medicaid Services; FFS  fee for service; NCDR  National Cardiovascular Data Regiented as medians with interquartile percentiles, and cate-
orical variables are presented as percentages. Differences
etween patient groups were compared using chi-square
ests for categorical variables and the Wilcoxon rank sum
est for continuous variables, respectively.
Estimates of the event rates for clinical endpoints at 1
onth, 12 months, and 30 months post-intervention were
etermined on the basis of weights that were functions of
aplan-Meier censoring estimates (12). The cumulative
ncidence rates for time-to-event clinical outcomes were
stimated by using Gray’s method (13). Both the unadjusted
nd adjusted hazard ratios were estimated for in-hospital
leeding versus no bleeding along with a 95% confidence
nterval on the basis of the sandwich-estimated standard
rrors. The adjusted analysis include the variables adopted
n the CathPCI Registry in-hospital all-cause mortality
odel as covariates, which consist of age, body mass index,
lomerular filtration rate, ST-segment elevation myocardial
nfarction (STEMI), cardiogenic shock at admission, med-
cal history (i.e., congestive heart failure, valvular surgery,
erebrovascular disease, peripheral vascular disease, chronic
ung disease, diabetes, dialysis, PCI), highest-risk lesion
haracteristics (segment category), New York Heart Asso-
iation functional class, pre-procedure intra-aortic balloon
ump, coronary lesion 50%, and PCI status (14). In
ddition, we used landmark analysis to determine the
0-month component of the in-hospital bleeding effect after
xcluding events between 30 days and 12 months. The
ntire analysis was repeated to examine the relationship
ded. ACC  American College of Cardiology; CMS  Centers for Medicare &inclu
stry; PCI  percutaneous coronary intervention.
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961between access site and non-access site bleeding and the
outcomes, using no bleeding as the reference. A p value
0.05 was considered significant for all tests. The Duke
Clinical Research Institute performed all statistical analyses
using SAS software (version 9.2, SAS Institute, Cary, North
Carolina).
Results
Patient sample and baseline characteristics. The final study
ample included 837,733 patients from 964 sites. After
atching to Medicare claims, the analysis dataset included
61,311 patients from 946 sites (Fig. 1), 14,107 (3.1%) of
hom experienced bleeding. Among patients who bled,
Table 1. Baseline Characteristics of Patients Who
Characteristic
Demographics
Age, yrs
Female
BMI, kg/m2 2
Medical comorbidities
Diabetes mellitus
Hypertension
Peripheral arterial disease
Chronic kidney disease
Prior CHF
Prior PCI
Prior CABG
Procedure characteristics
Procedure indication
Stable angina/atypical chest pain/asymptomatic
Non–ST-segment ACS
STEMI
Procedure status
Elective
Urgent
Emergency
Medications*
Aspirin
Clopidogrel
Unfractionated heparin
LMWH
Bivalirudin
Any GP IIb/IIIa
Vascular access site
Radial
Femoral
Brachial
Values are median (interquartile range) or percentages. *Includes m
ACS  acute coronary syndrome; BMI  body mass index; CA
glycoprotein; LMWH  low-molecular-weight heparin; PCI  perinfarction.8.6% had access site bleeding. The rate of blood transfu-
ion was 5.5%. Baseline characteristics of the patients who
id and did not develop bleeding are listed in Table 1.
atients who bled were older and more often female.
hey also had a lower body mass index, and more often
ad comorbidities, such as chronic kidney disease, pe-
ipheral arterial disease, cerebrovascular disease, and
ongestive heart failure. By contrast, there was a similar
revalence of diabetes mellitus and hypertension between
he 2 groups.
With respect to presenting symptoms, patients who bled
ore often presented with acute coronary syndrome (either
on-STEMI or STEMI) rather than stable angina. In
ddition, there was a higher proportion of urgent, emergent,
d Did Not Develop In-Hospital Bleeding
erall
61,311)
Bleeding
(n  14,107)
No Bleeding
(n  447,204) p Value
.0–80.0) 76.0 (71.0–81.0) 74.0 (69.0–80.0) 0.001
2.0 57.5 42.5 0.001
.7–31.5) 27.3 (24.0–31.3) 27.7 (24.7–31.5) 0.001
3.5 33.7 33.5 0.593
2.0 82.5 82.0 0.145
5.3 17.9 15.2 0.001
7.0 10.1 6.9 0.001
2.7 81.1 72.5 0.001
9.6 20.6 29.9 0.001
3.1 17.4 23.3 0.001
7.3 23.0 37.6 0.001
1.3 50.5 51.4 0.001
1.5 26.5 11.0 0.001
8.4 29.1 49.0 0.001
8.5 40.5 38.5 0.001
2.9 29.8 12.4 0.001
0.2 91.2 90.1 0.001
6.5 73.6 76.6 0.0001
3.8 69.4 53.3 0.001
6.7 20.6 16.6 0.001
0.8 27.5 41.2 0.001
8.2 61.3 37.4 0.001
1.2 0.8 1.2 0.001
7.9 97.9 97.9 0.863
0.4 0.7 0.4 0.001
ons given at the time of admission through the catheterization lab visit.
oronary artery bypass grafting; CHF  congestive heart failure; GP 
us coronary intervention; STEMI  ST-segment elevation myocardialDid an
Ov
(n  4
74.0 (69
4
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962and salvage procedures among patients who developed
bleeding. In-hospital medical therapies and procedural ap-
proaches also differed between the groups: the use of
unfractionated heparin, low-molecular-weight heparins,
and glycoprotein IIb/IIIa inhibitors was higher among
patients who bled. In contrast, the use of bivalirudin,
pre-PCI clopidogrel, and radial access was lower.
Table 2 displays the use of evidence-based medications at
he time of hospital discharge among patients who bled
ersus those who did not. The use of antiplatelet agents and
ther secondary prevention medications was significantly
ower among patients who bled, with the exception of
eta-blockers and angiotensin-converting enzyme inhibi-
ors, which were prescribed more often to patients who
eveloped a bleeding complication. The hospital length of
tay was significantly longer for patients who developed
leeding compared with those who did not (median length
f stay: 6.0 vs. 2.0 days, p  0.0001).
Outcomes. The unadjusted rates of the outcomes are listed
in Table 3. The rates of readmission for bleeding at 1
month, 12 months, and 30 months were significantly higher
Table 2. Unadjusted Rates of Evidence-Based Medic
Hospital Length of Stay Between Groups
Outcome
In-Hospital B
(n  14,
Discharge medications
Aspirin 94.6
Clopidogrel 92.2
Beta-blocker 85.8
Statin 81.0
ACE inhibitor 52.5
Median post-procedure LOS, days 6.0 (4.0–
Values are % or median (interquartile range).
ACE angiotensin-converting enzyme; LOS length of stay.
Table 3. Rates of the Primary and Secondary Clinica
Outcome
In-Hospital Bleedin
(n  14,107)
Readmission for bleeding
1 month 0.9 (0.7–1.0)
12 months 3.9 (3.5–4.3)
30 months 5.9 (5.2–6.6)
MACE*
1 month 6.7 (6.2–7.2)
12 months 30.6 (29.5–31.7)
30 months 51.4 (49.4–53.3)
All-cause mortality
1 month 2.3 (2.1–2.6)
12 months 13.7 (13.1–14.3)
30 months 24.1 (23.2–25.0)
Values are % (95% confidence intervals). *Death, MI, revascularizationMACEmajor adverse cardiac events; MImyocardial infarction.among patients who experienced in-hospital bleeding. Sim-
ilarly, unadjusted MACE and all-cause mortality rates at 1
month, 12 months, and 30 months were also significantly
higher among patients who developed in-hospital bleeding.
Figures 2A to 2C show the Kaplan-Meier rates of the
endpoints.
Adjusted results. Figure 3 displays the association between
post-procedure bleeding and readmission for bleeding, all-
cause mortality, and MACE after adjustment for potential
confounders. Compared with patients who did not bleed,
the risk for all 3 outcomes was significantly higher at all 3
time points for patients who experienced in-hospital bleed-
ing. At the 30-month time point, the risk for recurrent
bleeding and all-cause mortality attenuated slightly, but was
still significantly higher for patients who bled compared
with patients who did not bleed. The risk for MACE
remained stable over time and was significantly higher for
patients who bled compared with those who did not bleed.
The relationships between access site and non-access site
bleeding and outcomes are shown in Online Table 1 in the
Online Appendix.
at Discharge and Differences in
g No In-Hospital Bleeding
(n  447,204) p Value
95.6 0.001
95.7 0.001
80.1 0.001
82.2 0.001
48.5 0.001
2.0 (2.0–3.0) 0.001
oints Between Groups
No In-Hospital Bleeding
(n  447,204) p Value
0.3 (0.3–0.4) 0.001
1.9 (1.9–2.0) 0.001
3.4 (3.3–3.5) 0.001
5.7 (5.6–5.8) 0.001
24.1 (23.9–24.3) 0.001
43.5 (43.2–43.9) 0.001
1.0 (1.0–1.1) 0.001
6.9 (6.8–6.9) 0.001
14.2 (14.1–14.3) 0.001ations
leedin
107)
9.0)l Endp
g
.
cedural bleeding and those who did not.
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963Discussion
In the largest analysis of its kind involving over 400,000
older patients, we found that post-PCI bleeding is associ-
ated with an increased risk for future bleeding complica-
tions, MACE, and all-cause mortality. Although the asso-
ciation between bleeding and long-term mortality among
patients undergoing PCI has been previously described, the
present study has 2 important new findings: 1) the associ-
ation between post-procedure bleeding and outcomes ex-
tends out to 30 months; and 2) patients who develop
post-procedure bleeding are prone to recurrent bleeding
events over the long term. Thus, post-procedure bleeding
identifies a patient population that is at risk for poor net
adverse clinical events.
The association between bleeding and ischemic out-
comes has been previously described. Kinnaird et al. (15)
examined the association between Thrombolysis In Myo-
cardial Infarction (TIMI) major and minor bleeding, as
well as blood transfusion, and in-hospital and 1-year
mortality among 10,974 unselected patients undergoing
PCI and found that TIMI major bleeding was indepen-
dently associated with in-hospital, but not 1-year, mor-
tality. By contrast, blood transfusion was associated with
increased mortality at both time points. Subsequent studies using
different bleeding definitions have found that bleeding and
transfusion are associated with short- and long-term mor-
tality, MACE, target vessel revascularization, stent throm-
bosis, and stroke (16–18). Yet none of these studies exam-
ined the risk of recurrent bleeding. Our study, which is
larger than all previous studies combined, confirms the
findings of prior studies, but also extends them by demon-
strating that bleeding identifies a group that is at high risk
for continued bleeding events in the outpatient setting.
Putative mechanisms that underlie the association be-
tween hemorrhagic complications and ischemic outcomes
include cessation of evidence-based therapy (2), the negative
effects of blood transfusion (1,19), a direct effect of the
bleeding itself on oxygen delivery or, rarely, exsanguination,
and potentially an increased propensity for thrombosis, due
to bleeding. Studies have explored these mechanisms in the
inpatient setting, but little is known about the mechanisms
that apply in the outpatient setting. With respect to recur-
rent bleeding events, it is likely that patients who are
vulnerable to bleeding from acute antithrombotic therapy
and invasive procedures are also susceptible to bleeding with
chronic antithrombotic therapies. In the present study,
patients who developed a bleeding complication were older,
more often had a lower body weight, and more often had
comorbidities, such as chronic kidney disease, diabetes, and
peripheral arterial disease. Many of these risk factors are
associated with bleeding during chronic therapy with dual
antiplatelet therapy (7). This consistency in characteristicsFigure 2. Kaplan-Meier Rates
(A) Kaplan-Meier rates of readmission for bleeding between patients who
developed periprocedural bleeding and those who did not; (B) Kaplan-
Meier rate of major adverse cardiac events (MACE) between patients who
developed periprocedural bleeding and those who did not; (C) Kaplan-
Meier rates of all-cause mortality between patients who developed peripro-associated with bleeding across care settings underscores the
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964importance of monitoring these high-risk patients for both
ischemic and bleeding complications from the time of PCI
through long-term outpatient follow-up.
In the contemporary era of PCI, several strategies exist to
reduce the risk of periprocedural bleeding (20,21). Clinical
trials have shown that some of these strategies are associated
with reduced all-cause mortality in specific settings (22,23).
For example, the use of bivalirudin is associated with a
significant reduction in both access site and non-access site
bleeding (24), and is associated with reduced short- and
long-term mortality among patients undergoing primary
PCI (25). Similarly, the use of radial access is also associated
with a significant reduction in access site bleeding and
vascular complications, but is less frequently used in patients
at higher risk for such complications (26). Although these
strategies reduce the risk for in-hospital bleeding, neither is
applicable in the outpatient setting. There are few proven
approaches associated with reduced bleeding risk during
chronic treatment for coronary artery disease. Reduction in
aspirin dosing may be associated with lower bleeding rates
during long-term therapy (27), but not within 30 days of an
acute coronary syndrome episode (28). Another strategy is
to avoid the use of potent thienopyridines in patients at high
risk for bleeding, such as older patients, those with prior
stroke or transient ischemic attack, and those with body
Figure 3. Adjusted Association Between In-Hospital Bleeding, Recurrent B
Hazard ratios for outcomes are shown with landmarks at 30 days and 1 year. A
class, diabetes, prior CHF, BMI, dialysis, GFR, PAD, CVD, urgent PCI, shock, eme
ease, race, STEMI, TIMI ﬂow, and stent thrombosis. MACE adjusted for diabetes
NYHA functional class, emergent PCI, pre-PCI IABP, shock, TIMI ﬂow grade, urg
thrombosis. BMI  body mass index; CHF  congestive heart failure; CVD  c
IABP  intra-aortic balloon pump; MACE  major adverse cardiac event; NYHA
neous coronary intervention; STEMI  ST-segment elevation myocardial infarcweight 60 kg (29). Ticagrelor, a non-thienopyridineP2Y12 antagonist, has been shown to reduce ischemic
events, including stent thrombosis, over the long term
without an increase in major bleeding (30), and this agent
may be preferred in patients at risk for bleeding.
Study limitations. First, we relied on linkage to administrative
ata to obtain long-term outcomes. This necessarily limited
ur population to patients who were age 65 years or older. In
ddition, nonmortal events, such as bleeding, revascularization,
r MI were obtained from Medicare data, which may lead to
issing events due to coding bias. We also could not com-
letely account for differences in severity across events defined
y the ICD-9 codes. Second, we did not have data on patient
railty, which may account, in part, for the outcomes. Third,
lthough it is possible that some of the bleeding events that
ccurred during follow-up may have been associated with
epeat percutaneous procedures, we minimized this possibility
y limiting the bleeding outcomes to hospitalization specifi-
ally for a bleeding event. Finally, unmeasured confounders
ay be present. To minimize this, we used a robust statistical
djustment; however, causality cannot be inferred from our
ndings.
onclusions
Among older patients, post-PCI bleeding complications are
g, MACE, and All-Cause Mortality
se mortality adjusted for age, chronic lung disease, EF, NYHA functional
PCI, sex, primary PCI, lesion risk, pre-PCI IABP, salvage PCI, prior valve dis-
ialysis, lesion risk, chronic lung disease, prior CHF, BMI, PAD, CVD, GFR,
I, age, STEMI, primary PCI, salvage PCI, race, prior valve disease, and stent
vascular disease; EF  ejection fraction; GFR  glomerular ﬁltration rate;
ew York Heart Association; PAD  peripheral artery disease; PCI  percuta-
IMI  Thrombolysis In Myocardial Infarction.leedin
ll-cau
rgent
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 Nassociated with an increased risk for short- and long-term
22
2
2
3
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 9 , 2 0 1 2 Rao et al.
S E P T E M B E R 2 0 1 2 : 9 5 8 – 6 5 Periprocedural Bleeding
965readmission for bleeding, MACE, and all-cause mortality.
These data underscore the prognostic importance of bleed-
ing and the need for identifying strategies to reduce both
procedural and long-term bleeding risk among patients
undergoing PCI.
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